NEW YORK (Reuters) - Eli Lilly & Co on Tuesday will confront the first U.S. trial over allegations it failed to warn users of its popular antidepressant Cymbalta that they could suffer severe ...
The largest review of ‘gold standard’ antidepressant withdrawal studies to date has identified the type and incidence of symptoms experienced by people discontinuing antidepressants, finding most ...
NEW YORK (MedscapeWire) Nov 26 — Data on duloxetine, an investigational balanced serotonin and norepinephrine reuptake inhibitor, suggest it is more effective than placebo and paroxetine in reducing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results